Efficacy and Safety Study of DERMAGEN® vs Conventional Treatment to Treat Diabetic Neuropathic Foot Ulcer

Inclusion Criteria: * Female or male patient aged ≥ 18 * Patient with documented and stable\* type I or II diabetes mellitus * With diagnosis of neuropathic foot ulcer located on the plantar surface of the forefoot * Ulcer with a surface area comprised between 1 and 15 cm2 included (after mechanical debridement of the ulcer) * Palpable pulse evidenced on both feet (presence of dorsalis pedis pulse and posterior tibial pulse) or in absence of one pulse, a Systolic Pressure Index (SPI) by Doppler \> 0.9 on the target limb * Presence of diabetic foot ulcer for at least 4 weeks prior to enrolment * Patient's ulcer extending through the dermis without exposure of muscle, tendon, bone, or joint capsule \*means confirmed by HbA1C at least every 4 months Exclusion Criteria: * Typical Charcot's foot * Decrease or increase in the size of the ulcer by 50% or more during the run-in period * Presence of osteitis (eq Br osteomyelitis) at the inclusion visit (evidenced with a radiological lesion facing the wound (bone erosion or disappearance of the cortical bone)) * Clinical evidence of Pedis grade 3, or 4 infection at the inclusion visit * Patient who cannot have an off-loading method * Patient with working activity who cannot be on sick-leave during the study period. * Patient presenting a known allergy to collagen, streptomycin, penicillin and/or products of bovine origin * Dialysed patient * Patient suffering from a psychiatric disorder not treated * Clinical evidence of gangrene on any part of the affected foot * Patient receiving corticosteroids, NSAIDs, immunosuppressive or cytotoxic agents, all systemic agents that can affect wound repair or any treatment that might interfere with the assessment of the study treatment